Trial Profile
A Phase II Study of Ofatumumab-High Dose Methylprednisolone Followed by Ofatumumab-Alemtuzumab in 17p Deletion CLL
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Ofatumumab (Primary) ; Alemtuzumab; Methylprednisolone
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 06 Jun 2019 Status changed from active, no longer recruiting to discontinued.
- 25 May 2017 Status changed from recruiting to active, no longer recruiting.
- 06 May 2016 Status changed from active, no longer recruiting to recruiting.